This #WorldHealthDay, see how we’re continuing our pledge to foster health equity, empower our healthcare workers, and improve healthcare accessibility for all: social.jnj.com/49toYhS

Join us tomorrow at 8:30 AM ET for a live call and webcast as we share our Q1 2024 results. Register here: social.jnj.com/3UeDYuL $JNJ #earnings

New: We’ve announced our Q1 2024 performance results. See the release for full financial details and non-GAAP reconciliations: social.jnj.com/3xDhonJ $JNJ #earnings

Join our Q1 2024 #earnings call and webcast now: social.jnj.com/3xxGzYQ $JNJ

Joaquin Duato, Chairman of the Board and Chief Executive Officer, #JNJ, on our Q1 2024 #earnings and financial performance. $JNJ

Joe Wolk, Executive Vice President and Chief Financial Officer, #JNJ, on our Q1 2024 #earnings and financial performance. $JNJ

See a recap of our Q1 2024 #earnings here: social.jnj.com/4cZxOHd $JNJ

We're connecting the best of Health&Care to bring patients and providers around the globe advanced treatments and industry-leading solutions. See how: social.jnj.com/49RiABi

Johnson & Johnson has entered into a definitive agreement to acquire Proteologix, Inc., a biotechnology company focused on bispecific antibodies for immune-mediated diseases. Click here for more information: social.jnj.com/3WK4BdH #JNJImmunology #Innovation

.Johnson & Johnson MedTech completed its acquisition of Shockwave Medical, a pioneer in the development of transformational technologies for the treatment of cardiovascular disease. Click here for more information: social.jnj.com/3VnOPEc

We're connecting the best of Health&Care to bring patients and providers around the globe advanced treatments and industry-leading solutions. See how: social.jnj.com/3yJwubZ

NEW: Discover how we're closing the gap between communities and care to create a healthier, more sustainable future in our 2023 #HealthForHumanity report: social.jnj.com/3KsJNjt

We are proud to share that our VELYS™ Robotic-Assisted Solution for Unicompartmental Knee Arthroplasty (UKA) has received 510(k) FDA clearance. This latest MedTech advancement underscores our commitment to #KeepPeopleMoving. Learn more: bit.ly/4b0wamI.

Join us tomorrow at 8:30 AM ET for a live call and webcast as we share our Q2 2024 results. Register here: social.jnj.com/3S4IsDE $JNJ #earnings

New: We’ve announced our Q2 2024 earnings results. See the press release for financial details, non-GAAP reconciliations and cautionary statements: social.jnj.com/3LrqxDv $JNJ #earnings

Join our Q2 2024 #earnings call and webcast now: social.jnj.com/3LiPwc3 $JNJ

Joaquin Duato, Chairman and Chief Executive Officer, #JNJ, on our Q2 2024 #earnings results. Read the release for details, non-GAAP reconciliations and cautionary statements: social.jnj.com/3y0Es0c $JNJ

Joe Wolk, Executive Vice President and Chief Financial Officer, #JNJ, on our Q2 2024 #earnings results. Check out our Investor Relations site for more information: social.jnj.com/4cRHiDq $JNJ

See a recap of our Q2 2024 #earnings here: social.jnj.com/3zOkR3Z $JNJ

We’ve entered into an agreement to acquire V-Wave, a company developing innovative treatment options for patients with heart failure. Click here for more information: social.jnj.com/46Q6fgV